Radiation for wet AMD has a long history involving multiple modalities—EBRT using megavoltage x-rays, proton beam therapy, and brachytherapy—all with limited functional success with respect to visual acuity outcomes.
7 –9,15,20 –27 Historically, an anatomic signal has been noted, manifesting in choroidal neovascular regression on fluorescein angiography in some proportion of patients. The feared complication with respect to retina is the development of radiation retinopathy, whose mechanism involves preferential damage to small-diameter vessels and their supporting cells.
28 –30 However, despite the widespread fear of radiation retinopathy, it has not been reported in the 11 studies of 1154 patients treated with EBRT
21,27 or in the cases of plaque brachytherapy.
8,22,31,32 One case of self-limited radiation retinopathy was reported with
90Sr brachytherapy.
15,25,26 When examining proton beam radiotherapy, the reported rates of radiation retinopathy range from 14% to 50%. The main difference in these modalities appears to be the volume of retina irradiated. For the IRay device, the 90th isodose curves correspond to a volume of 3.14 mm
3 based on 4-mm spot size and a 250-μm retina thickness. For EBRT, the spot sizes are 12 mm, resulting in a volume of retina treated 10 times greater. For proton beam, the entire retina receives at least a 10% dose,
33 resulting in a 100-fold increase in volume of retina treated.
Given the data available in the literature pertaining to the development of radiation retinopathy from radiation-based modalities used previously and considering that the gross treatment volume is significantly reduced by the stereotactic targeting capabilities of the IRay system, dose considerations to the retina were not included in the present study. Instead, the development of the 16-patient, 32-eye model library presented here allows for the study of dose distributions and risk assessments to nontargeted, radiosensitive structures, such as the lens and optic nerve, and several other trends related to gaze angle during clinical treatment.
The results of the present study suggest a loose correlation between gaze angle and optic nerve position. As gaze angle shifts, the optic nerve reacts accordingly by being “stretched” in the opposite direction. Thus, for an upward vertical gaze, the optic nerve would have a superiorly tilted exit angle, and for a downward vertical gaze, it would have an inferiorly tilted exit angle. For an inward (medial) horizontal gaze, the optic nerve would increase the degree of tilt in the medial direction from its reference position, which is already tilted approximately 22.4° in the medial direction. For an outward (lateral) horizontal gaze, the optic nerve will reposition itself with a smaller tilt angle with respect to its reference position in the medial direction. The R 2 values are well below the value that would be characterized as a statistically significant correlation, indicating that not all optic nerves have the same reference position and may react differently to changes in gaze angle. Additionally, for the optic nerve to be able to react to changing gaze, there must be some “slack” in the optic nerve in the reference or primary gaze position. The position in which this slack comes to rest may depend on the last direction in which the person gazed or on the person's head orientation with respect to gravity if sufficient time is allowed for the optic nerve to readjust itself within the orbital fat. Furthermore, it may seem counterintuitive that the distribution of horizontal gaze angles is centered over a negative value, favoring a lateral gaze. However, in this study, gaze angle was defined using the volume centroids of the lens and globe (geometric axis) that were not coincident with the fovea (visual axis). Because the fovea is located lateral to the posterior pole, which also intersects the geometric axis, defining true gaze angles using the visual axis would shift the distribution medially. In this scenario, the true gaze would be dependent on the distance to the object of focus, which has no relevance in the clinic or for treatment planning.
The radiologic sensitivity of the optic nerve has been studied in patients whose optic nerve was unavoidably or unintentionally irradiated as a consequence of brain or head tumor radiotherapy, showing that doses ≥8 Gy might have some adverse consequence.
34 Another study found that doses <12 Gy to a short segment of the anterior optic apparatus during stereotactic radiosurgery resulted in a low risk (∼1.1%) for radiation-induced optic neuropathy (RON); however, 3 of 4 patients with RON in this study had previously undergone EBRT, and the other had undergone two previous radiosurgery procedures.
35 It is also unclear what percentage of volume characterized the short segment of the anterior optic apparatus. Ultimately, the authors conclude that point doses up to 12 Gy are well tolerated by patients whose optic nerve has not been previously irradiated. Furthermore, a recent study
36 suggests that the optic apparatus may be more tolerant to radiation than previously thought and able to receive up to 14 Gy without risk for RON (again under the assumption that the patient has not previously undergone radiation therapy).
Despite the variability of the location of the optic nerve observed in this study, the highest cumulative tissue-averaged dose received was 1.3 Gy, by model
fkl (
Table 3), which is well below the threshold for RON. Dose contour maps were created for this patient (
Fig. 5), and it can be seen that the overlapping beams avoided the optic nerve. This patient demonstrated a lateral horizontal gaze of roughly 16°, outside the range of clinically relevant horizontal gaze angles. It is unclear from the literature what maximum point dose is tolerated by the optic nerve; nevertheless, it is reasonable to assume that the risk for RON was negligible for all simulated patient models in this study given the dose volume data presented in
Table 1.
The tissue-averaged dose threshold for radiation cataractogenesis is 700 mGy.
37 The highest tissue-averaged dose observed in the present study was 176 mGy (
Table 3). Eye model
fjl had the highest percentage of volume receiving in excess of doses 300 mGy, and no lens volume received a dose over 400 mGy (
Table 2). The sagittal dose contour map and the most inferior voxelized slice that contains the lens of patient
fjl are shown in
Figure 6, and both clearly depict that the converging beams do not directly intersect the lens.
The development of necrosis in brain tissue from radiologic toxicity is well documented in the literature, as summarized by Lawrence et al.,
38 and it has been determined that the threshold for neurologic toxicity is 12 Gy for a volume between 5 and 10 cm
3. No brain voxels received a dose greater than this threshold in this computational study.
One patient (
fdl) in this study received a localized point dose (1.125 mm
3) to the orbital bone between 45 and 50 Gy. Bone, and in this case orbital bone, contains elements with higher atomic numbers that have a higher cross-section (probability) for photon interaction, namely the photoelectric effect, than seen in soft tissue and fat. The resultant secondary particles (electrons) are likely to deposit their energy locally, and, as such, the bone absorbs more dose than surrounding tissues. However, the skull is fairly radio-resistant to adverse consequences, and orbital bone contains a negligible percentage of the total active marrow in the cranium.
39,40
An attempt was made to find correlations between absorbed dose to nontargeted tissues and the measurement parameters mentioned earlier. For most tissues, we found no statistically significant relationships. Analysis of optic nerve data provided two significant correlations: optic nerve dose varied as a function of optic nerve thickness (
Fig. 7) and gaze angle (
Fig. 8). The former relationship is intuitive; the optic nerve dose will escalate with increasing optic nerve thickness. The latter may not be intuitive at first but becomes clearer with better understanding of optic nerve tilt as a function of gaze angles. The logarithmic regressions suggest that optic nerve dose increases as vertical and lateral gazes increase (negative values in
Fig. 8B are lateral). As described, an increasing vertical gaze will stretch the optic nerve into a more vertical exit tilt, which would position the optic nerve closer to the beams exiting the eye. As lateral gaze increases, the optic nerve tilt decreases (approaching a limit of being positioned in parallel with the sagittal reference plane) and positions itself closer to the beam entering from the lateral side (exiting medially from the eyeball).
The dosimetry performed for kilovoltage stereotactic radiosurgery treatment simulation (n = 32) showed that tissues at risk do not receive tissue-averaged doses greater than the generally accepted thresholds for complications, specifically the formation of cataracts and brain necrosis. Similarly, point doses delivered to the optic nerve were not significant in terms of the risk for RON. This study provided a worst-case scenario risk assessment by including a range of clinically unrealistic gaze angles and, correspondingly, a diverse range of optic nerve positions. Ultimately, the treatment scheme used by the IRay device has the potential to deliver a therapeutic dose to the macula with minimal irradiation of nontarget tissues within a set limit of clinically realistic gaze angles. Furthermore, the doses reported in this study could be scaled proportionally for a cumulative therapeutic dose of 16 Gy to the macula tissue, the treatment scheme currently planned for US clinical trials.
Supported by Oraya Therapeutics, Inc. Grant ORAYA-001-2007.
Disclosure:
J. Hanlon, Oraya Therapeutics, Inc. (F);
M. Firpo, Oraya Therapeutics, Inc. (I, E);
E. Chell, Oraya Therapeutics, Inc. (I, E);
D.M. Moshfeghi, Oraya Therapeutics, Inc. (F, C);
W.E. Bolch, Oraya Therapeutics, Inc. (F)